Drug intelligence / Profile preview

MCX201

Development stage: Preclinical
Lead developer: mCureX
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

MCX201 is an mRNA-based therapeutic currently in the drug discovery stage of development by mCureX Therapeutics, a South Korean biotechnology company and subsidiary of OliX Pharmaceuticals. The drug is being developed for the treatment of various neoplasms (cancer) using mCureX's proprietary mRNA platform technology, which incorporates modified nucleotides to enhance the stability and expression of the therapeutic payload while minimizing unwanted immunogenicity. While the specific molecular targets, mechanism of action, and targeted cancer subtypes have not been publicly disclosed, the program represents the company's strategic expansion of its mRNA technology from infectious disease vaccines into the oncology space.

Beyond the preview

Go deeper on MCX201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCX201.

Explore the full profile